Ascletis announces signing of Ritonavir tablet purchase agreement with Phokam Pharmaceutical

Ascletis Pharma Inc recently announced the signing of the Ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export (as buyer) of Laos and Ascletis Pharmaceuticals (as seller), a wholly-owned subsidiary of Ascletis Pharma Inc.

In a statement, Ascletis Pharma said that Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targetting viral proteases. Ritonavir oral tablet is a component of oral antiviral drug Paxlovid.

Ascletis sells ritonavir oral tablets worldwide. Ascletis owns the only authorised Ritonavir oral tablet in China, which passed bioequivalence study. Ascletis’ ritonavir oral tablet was approved in September 2021 by China National Medical Products Administration. The company applied the sophisticated formulation technology to significantly increase the human bioavailability of Ritonavir which has a poor solubility and successfully achieved human bioequivalence with the Ritonavir oral tablets produced by the originator, AbbVie, the statement further said.

It also said that Ascletis is planning to file generic drug applications for registrations in multiple countries worldwide. On 3rd January, 2022, the company announced that Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand.